FEROZSONS
LABORATORIES LIMITED

60 YEARS OF TRUST & DEVOTION

September 21, 2019 COR/2019/09-11

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.

Subject: **Financial Results for the Year Ended June 30, 2019**

Dear Sir,

We have to inform you that the Board of Directors of our Company in their meeting held on September 21, 2019 at 2:00 P. M. at 5-KM, Sunder Raiwind Road, Lahore, recommended the following:

CASH DIVIDEND

A final Cash Dividend for the year ended June 30, 2019 at Rs. 4.00 per share i.e. 40%. This is in addition to Interim Dividend already paid at Rs. 2.00 per share i.e. 20%.

The financial results of the Company are attached. Company's individual and consolidated Profit and Loss Account for the year ended June 30, 2019 with comparison of corresponding year is enclosed.

The Annual General Meeting of the Company will be held on October 25, 2019 at 11:45 A.M. at Rawalpindi.

The above entitlement will be paid to the shareholders whose name will appear in the Register of Members on October 17, 2019.

The Share Transfer Books of the Company will be closed from October 18, 2019 to October 25, 2019 (both days inclusive). Transfers received at the Office of the Company's Share Registrar, CorpTec Associates (Pvt.) Limited, 503-E, Johar Town, Lahore at the close of business on October 17, 2019 will be treated in time for the purpose of above entitlement to the transferees.

The Annual Report of the Company will be transmitted through PUCARS atleast 21 days before holding of Annual General Meeting.

Yours truly,

Syed Ghausuddin Saif
Company Secretary

Encl.

REGISTERED QUALITY SYSTEM ISO 9001 SGS

Head Office/Biotech Factory: 5-K.M- Sunder Raiwind Road Raiwind Lahore, Pakistan.
Office phones: +92-42-36026700
Fax: +92-42-36026701-2
Factory phones: +92-308-5053135
Fax: +92-42-36026791

Registered Office: 197-A,The Mall Rawalpindi,46000 Pakistan.
Phones: +92-51-4252155-57
Fax: +92-51-4252153

Pharma Factory: P.O. Ferozsons, Amangarh-Nowshera, (KPK) Pakistan.
Phones: +92-923-560141, +92-923-560145, +92-923-560148, +92-923-560056

Lahore Sales Office: 43-Al Noor Building, Bank Square, The Mall, Lahore, Pakistan.
Phones: +92-42-37358194
Fax: +92-42-37313680

Karachi Sales Office: House No.9, Maqbool Corporative Society Shahrah-e-Faisal Karachi, Pakistan.
Phones: +92-21-34386852
Fax: +92-21-34386754

email: info@ferozsons-labs.com www.ferozsons-labs.com

Ferozsons Laboratories Limited
Unconsolidated Statement of Profit or Loss
For the year ended 30 June 2019

	Note	2019 Rupees	2018 Rupees
Sales - net	22	**5,180,803,582**	4,409,137,684
Cost of sales	23	**(3,134,954,617)**	(2,908,895,564)
Gross profit		**2,045,848,965**	1,500,242,120
Administrative expenses	24	**(353,172,864)**	(303,096,037)
Selling and distribution expenses	25	**(1,309,653,498)**	(1,056,932,024)
Other expenses	26	**(123,265,414)**	(50,987,393)
Other income	27	**182,390,571**	129,086,882
Profit from operations		**442,147,760**	218,313,548
Finance cost	28	**(23,429,965)**	(11,048,102)
Profit before taxation		**418,717,795**	207,265,446
Taxation	29	**(167,672,113)**	(111,859,642)
Profit after taxation		**251,045,682**	95,405,804
Earnings per share - basic and diluted	30	**8.32**	3.16

The annexed notes from 1 to 40 form an integral part of these unconsolidated financial statements.

Ferozsons Laboratories Limited
Consolidated Statement of Profit or Loss
For the year ended 30 June 2019

	Note	2019 Rupees	2018 Rupees
Sales - net	22	5,802,855,865	5,002,680,003
Cost of sales	23	(3,761,902,459)	(3,483,750,342)
Gross profit		2,040,953,406	1,518,929,661
Administrative expenses	24	(393,604,529)	(346,745,044)
Selling and distribution expenses	25	(1,353,585,894)	(1,161,081,590)
Other expenses	26	(142,957,501)	(53,114,850)
Other income	27	212,019,398	139,585,855
Profit from operations		362,824,880	97,574,032
Finance cost	28	(24,760,408)	(12,001,704)
Profit before taxation		338,064,472	85,572,328
Taxation	29	(150,069,156)	(102,583,964)
Profit / (loss) after taxation		187,995,316	(17,011,636)
Attributable to:			
Owners of the Group		200,775,867	7,076,033
Non-controlling interests		(12,780,551)	(24,087,669)
Profit / (loss) after taxation		187,995,316	(17,011,636)
Earnings per share - basic and diluted	30	6.65	0.23

The annexed notes from 1 to 41 form an integral part of these consolidated financial statements.